Outlook Therapeutics (OTLK) Interest & Investment Income (2023 - 2024)
Outlook Therapeutics (OTLK) posted quarterly Interest & Investment Income of $239951.0 for Q3 2024, down 21.59% year-over-year from $306021.0 in Q4 2023, and down 40.69% quarter-over-quarter from $404593.0 in Q2 2024.
Outlook Therapeutics (OTLK) Interest & Investment Income (2023 - 2024) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Interest & Investment Income for 2 consecutive years, with $239951.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Interest & Investment Income fell 21.59% year-over-year to $239951.0; the TTM figure through Sep 2024 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $89738.0, down 90.1% from the prior year.
- Interest & Investment Income declined to $239951.0 in Q3 2024 per OTLK's latest filing, from $404593.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $404593.0 in Q2 2024 and bottomed at $239951.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 239,951.00 |
| Jun 30, 2024 | 404,593.00 |
| Sep 30, 2023 | 306,021.00 |
| Jun 30, 2023 | 395,537.00 |